Inventor · disambiguated record
Haiqun Tang
Also filed as: TANG HAIQUN
15 granted patents·9 pending applications·38 citations·filing 2002–2023
89Inventor score
Files withMERCK SHARP & DOHME9SCHERING CORP4ASBEROM THEODROS2DWYER MICHAEL P2MERCK SHARP & DOHME LLC2
Top patents by PatentIndex Score
24 records- 0190US10221163B2Metallo-beta-lactamase inhibitorsMERCK SHARP & DOHME·Filed 2016·Granted Mar 5, 2019·4 cites·67 claims
- 0286US9708336B2Metallo-beta-lactamase inhibitorsMERCK SHARP & DOHME·Filed 2015·Granted Jul 18, 2017·4 cites·26 claims
- 0386US9586948B2Inhibitors of IRAK4 activityMERCK SHARP & DOHME·Filed 2013·Granted Mar 7, 2017·7 cites·3 claims
- 0485US9839642B2Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitorsMERCK SHARP & DOHME·Filed 2015·Granted Dec 12, 2017·3 cites·19 claims
- 0583US10544130B2Metallo-beta-lactamase inhibitorsMERCK SHARP & DOHME·Filed 2019·Granted Jan 28, 2020·1 cites·20 claims
- 0680US8067621B2Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitorsASBEROM THEODROS·Filed 2007·Granted Nov 29, 2011·5 cites·48 claims
- 0779US7723342B2Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemiaSCHERING CORP·Filed 2006·Granted May 25, 2010·4 cites·61 claims
- 0878US8927559B2Quinazolinone-type compounds as CRTH2 antagonistsASLANIAN ROBERT G·Filed 2011·Granted Jan 6, 2015·6 cites·16 claims
- 0977US10227331B2Metallo-β-lactamase inhibitorsMERCK SHARP & DOHME·Filed 2016·Granted Mar 12, 2019·1 cites·26 claims
- 1073US10414774B2Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc diseaseMERCK SHARP & DOHME·Filed 2017·Granted Sep 17, 2019·1 cites·18 claims
- 1171US8569521B2Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitorsASBEROM THEODROS·Filed 2011·Granted Oct 29, 2013·2 cites·64 claims
- 1257US11207312B2Metallo-beta-lactamase inhibitors and methods of use thereofMERCK SHARP & DOHME·Filed 2018·Granted Dec 28, 2021·0 cites·14 claims
- 1357US2025099478A1Plasma kallikrein inhibitorsMERCK SHARP & DOHME LLC·Filed 2023·Application pending·0 cites
- 1452US2024025917A1Plasma kallikrein inhibitorsMERCK SHARP & DOHME LLC·Filed 2021·Application pending·0 cites
- 1551US2024174679A1Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereofCHILDERS KALEEN KONRAD·Filed 2022·Application pending·0 cites
- 1651US2024190892A1Plasma kallikrein inhibitorsCERNAKA NATALIJA·Filed 2022·Application pending·0 cites
- 1748US2010227873A1Nitrogen-containing heterocyclic compounds and methods of use thereofSCHERING CORP·Filed 2010·Application pending·0 cites
- 1844US2011152259A1Nitrogen-containing heterocyclic compounds and methods of use thereofPALANI ANANDAN·Filed 2011·Application pending·0 cites
- 1944US2020375987A1Metallo-beta-lactamase inhibitors and methods of use thereofPASTERNAK ALEXANDER·Filed 2018·Application pending·0 cites
- 2042US7361769B2Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disordersSCHERING CORP·Filed 2005·Granted Apr 22, 2008·0 cites·21 claims
- 2142US7348328B2MCH antagonists for the treatment of obesitySCHERING CORP·Filed 2002·Granted Mar 25, 2008·0 cites·10 claims
- 2241US2014378416A1Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseasesDWYER MICHAEL P·Filed 2012·Application pending·0 cites
- 2341US2015057246A1Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseasesDWYER MICHAEL P·Filed 2012·Application pending·0 cites
- 2438US10414775B2Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic diseaseMERCK SHARP & DOHME·Filed 2017·Granted Sep 17, 2019·0 cites·18 claims
Join the waitlist — get patent alerts
Get an alert when Haiqun Tang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →